All non‐frail patients (including four patients with ≥3 irAEs, one with grade 1 dermatitis, and one with grade 2 CIP) who were reactivated with the same PD‐1 inhibitor recovered from irAEs. This evidence concerns the gene PDCD1 and hereditary sensory and autonomic neuropathy.